FDA Inspection 1060107 — David M. Stoll, MD
The FDA completed an inspection of David M. Stoll, MD on Jun 22, 2018 in Beverly Hills, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jun 22, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Beverly Hills, CA (United States)
Additional Details
Clinical Investigator (CI)